Autolus Therapeutics (AUTL)

• Market cap: $383M
• 1 day: -2.04%
• 5 days: -2.7%
• 1 month: -3.36%
• 3 months: -10%
• 6 months: -5.26%
• Year to date: -22.99%
• 1 year: -44.83%
• 5 years: -75.72%
• 10 years: -94.24%
• Sector: Healthcare
• Industry: Biotechnology

About: Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Employees: 752